MATTHEW H. LIANG, M.D.; JAMES F. FRIES, M.D.
The management of asymptomatic hyperuricemia is controversial. Reported benefits from treatment include prevention of acute gouty arthritis, chronic tophaceous gout, urolithiasis, or gouty nephropathy. A review of experimental and clinical data suggests that the risks of asymptomatic hyperuricemia are small or unknown and the efficacy of long-term treatment in preventing gout or renal disease is unproved. The costs and risks of prolonged drug administration and practical considerations such as patient compliance mitigate against long-term therapy in asymptomatic persons. We offer some recommendations for an expectant approach to the management of asymptomatic hyperuricemia.
MATTHEW H. LIANG, JAMES F. FRIES. Asymptomatic Hyperuricemia: The Case for Conservative Management. Ann Intern Med. 1978;88:666–670. doi: 10.7326/0003-4819-88-5-666
Download citation file:
Published: Ann Intern Med. 1978;88(5):666-670.
Geriatric Medicine, Gout, Hospital Medicine, Nephrolithiasis, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use